INmune Bio (NASDAQ:INMB – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
Volatility and Risk
INmune Bio has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
Institutional & Insider Ownership
12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 35.2% of INmune Bio shares are owned by company insiders. Comparatively, 6.3% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INmune Bio | 0 | 0 | 5 | 1 | 3.17 |
| Protalix BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
INmune Bio currently has a consensus price target of $22.80, indicating a potential upside of 183.58%. Protalix BioTherapeutics has a consensus price target of $15.00, indicating a potential upside of 539.66%. Given Protalix BioTherapeutics’ higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than INmune Bio.
Profitability
This table compares INmune Bio and Protalix BioTherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| INmune Bio | N/A | -117.48% | -78.96% |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
Earnings and Valuation
This table compares INmune Bio and Protalix BioTherapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INmune Bio | $42,000.00 | 4,244.35 | -$30.01 million | ($2.18) | -3.69 |
| Protalix BioTherapeutics | $45.67 million | 3.78 | $8.31 million | ($0.13) | -18.04 |
Protalix BioTherapeutics has higher revenue and earnings than INmune Bio. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.
Summary
INmune Bio beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.
About INmune Bio
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.
